UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549


FORM 8-K


CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2014
______________________RBC Life Sciences, Inc.______________________
(Exact name of registrant as specified in its charter)
_______NEVADA_______
(State or other jurisdiction
of incorporation)
_______000-50417_________
(Commission
File Number)
_______91-2015186________
(IRS Employer
Identification No.)
2301 CROWN COURT, IRVING, TEXAS
(Address of principal executive offices)
____________75038_____________
(Zip Code)
Registrant's telephone number, including area code __________972-893-4000______________
__________________________N/A____________________________
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 18, 2014, the RBC Life Sciences, Inc. (the "Company") held its 2014 Annual Meeting of Shareholders (the "Annual Meeting") for the following purposes:

1.
To elect two (2) persons to serve as Class I directors of the Company until the earlier of the 2017 Annual Meeting of Shareholders, their successors are duly elected and qualified, or their resignation or removal from office; and
2.
To ratify the appointment of Lane Gorman Trubitt, PLLC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2014.
At the close of business on April 21, 2014, the record date of the Annual Meeting, the Company had 2,212,350 shares of common stock issued and outstanding. The holders of a total of 1,929,388 shares of common stock were present at the Annual Meeting, either in person or by proxy, which total constituted a majority of the issued and outstanding shares on the record date for the Annual Meeting.
With regard to the first proposal, all of the Company’s nominees for director were elected by the votes set forth in the table below:
Nominee
 
For
 
Withheld
 
Broker Non-Votes
Andrew V. Howard
 
1,494,250

 
250

 
434,888

Cynthia L. Tysinger
 
1,494,250

 
250

 
434,888


With regard to the second proposal, the appointment of Lane Gorman Trubitt, PLLC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2014 was ratified by the holders of a majority of the shares of Common Stock present at the Annual Meeting as set forth below:
For
 
Against
 
Abstain
1,502,468

 
405,527

 
21,393





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 20, 2014
                            
RBC Life Sciences, Inc.
 
By: /s/ Steven E. Brown
Name: Steven E. Brown
Title: President & Chief Financial Officer







RBC Life Sciences (CE) (USOTC:RBCL)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more RBC Life Sciences (CE) Charts.
RBC Life Sciences (CE) (USOTC:RBCL)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more RBC Life Sciences (CE) Charts.